0
0
NEW DELHI – A surge in geopolitical instability centered around the Strait of Hormuz is creating an unexpected crisis in the corridors of Indian hospitals. As of March 20, 2026, the Association of Indian Medical Device Industry (AiMeD) has issued an urgent briefing warning that the cost of raw materials for essential medical supplies has spiked by nearly 50%.
The disruption threatens the stability of the healthcare supply chain, raising the specter of nationwide shortages for “invisible” medical essentials—syringes, IV sets, and catheters—while potentially driving up out-of-pocket expenses for patients undergoing routine procedures.
The Vital Link: From Crude Oil to Catheters
The Strait of Hormuz serves as the world’s most sensitive transition point for oil, with approximately 20% of global petroleum passing through its narrow waters. While the public often associates this region with gasoline prices, the medical community views it through the lens of polymers.
Crude oil and natural gas are the primary feedstocks for plastics like polypropylene (PP), polyethylene (PE), and polyvinyl chloride (PVC). These materials are the literal building blocks of modern medicine. Currently, manufacturers report that domestic polymer prices have undergone multiple upward revisions, climbing by tens of thousands of rupees per metric tonne in just the first three weeks of March.
“When shipping routes are threatened, insurance premiums skyrocket and fuel surcharges follow,” explains Rajiv Nath, Forum Coordinator of AiMeD. “This creates a domino effect. Industrial gases used for sterilization and power generation have doubled in price, leaving manufacturers who operate on razor-thin margins in a precarious position.”
The Looming Threat of Shortages
While many large-scale manufacturers currently maintain inventory buffers that can absorb a one-to-three-week delay, experts warn that these reserves are a temporary dam against a rising tide.
Vulnerability of Public Hospitals
The most immediate concern lies within the public healthcare sector. Unlike private hospitals that may have more flexible procurement budgets, public facilities often operate on rigid, long-term tenders.
-
Fixed-Price Contracts: Many suppliers are locked into prices set months ago, before the 50% surge in raw material costs.
-
Stock-out Risks: If production becomes a net loss for manufacturers, they may be forced to scale back, leading to shortages of consumables used in blood draws, dialysis, and emergency surgeries.
A “Taxing” Situation for Manufacturers
Beyond the geopolitical friction, the Indian medical device industry is grappling with an internal structural hurdle: an inverted duty structure.
Under the current Goods and Services Tax (GST) regime, manufacturers pay an 18% tax on raw inputs (polymers and gases) but can only collect 5% GST on the finished medical devices sold to hospitals. This creates a massive backlog of unutilized tax credits, effectively “locking up” the working capital companies need to navigate the current price volatility. AiMeD has called on the government to expedite GST refunds to within seven days to provide a liquidity lifeline to the sector.
What This Means for Patients
For the average consumer, these high-level supply chain issues translate into three practical concerns:
-
Increased Out-of-Pocket Costs: In private healthcare settings, the cost of “consumables”—the items used once and discarded—may see a marked increase on final billing statements.
-
Procedure Delays: If a local clinic cannot secure a steady supply of specialized catheters or syringes, non-emergency elective procedures may be postponed.
-
Pressure on Rural Care: Smaller district hospitals, which lack the infrastructure to stockpile large quantities of goods, are typically the first to experience “stock-outs” during a national shortage.
“Medical devices are the invisible backbone of modern healthcare,” says Dr. Arvind Mehta, a public-health specialist and health-systems economist. “When their supply becomes unstable, even routine care can unravel. This episode highlights the urgent need for a strategic national stockpile of essential consumables.”
Counter-Perspectives and Limitations
While the situation is serious, some trade analysts urge a nuanced view. They suggest that while the Hormuz tensions are a primary catalyst, the price spikes are also influenced by seasonal domestic demand and global commodity cycles.
Furthermore, some critics argue that “price-gouging” by domestic polymer producers—rather than just logistics—is exacerbating the crisis. Major producers like Reliance Industries Limited have faced scrutiny from device makers who claim the magnitude of price hikes exceeds the actual increase in global crude costs.
Navigating the Crisis: A Guide for Consumers
While patients cannot control global shipping routes, they can take steps to manage their healthcare experience during this volatile period:
-
Transparency in Billing: When scheduling a procedure, ask for a cost breakdown. Inquire if the facility has implemented a “surcharge” on medical consumables due to recent supply chain shifts.
-
Utilize Public Schemes: Government-backed insurance and public hospitals are often better shielded from short-term price spikes due to bulk-buying power.
-
Advocate for Resilience: Support policy measures that encourage Atmanirbhar Bharat (Self-Reliant India) initiatives, which aim to reduce dependence on imported raw materials and streamline tax structures for domestic lifelines.
As the situation in the Middle East remains fluid, the Indian medical device industry stands at a crossroads. The ability of the government to provide tax relief and the industry’s capacity to diversify its material sources will determine whether this is a short-term hurdle or a long-term shift in the cost of Indian healthcare.
References
-
The Economic Times (Health), “Hormuz Tensions Push Device Costs Up 50%, Shortage Fears Rise,” published March 20, 2026.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
